TP53 and esophageal adenocarcinoma: In our study, the co-localisation of aberrant TP53 expression together with EGFR or HER2 gene amplification was noticed to be more common in the proximally than distally located intestinal-type tumours, which is in line with the results from a recent characterisation of oesophageal carcinomas showing strong genomic similarities between oesophageal adenocarcinomas and CIN-type gastric adenocarcinomas according to the TCGA classification [18].